Eesti - eesti - Ravimiamet

riga pharmaceutical plant - kamper - nahalahus - 20mg 1ml 40ml 1tk; 20mg 1ml 90ml 1tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - valsartaan+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 160mg+10mg+12,5mg 280tk; 160mg+10mg+12,5mg 98tk; 160mg+10mg+12,5mg 30tk; 160mg+10mg+12,5mg 56tk; 160mg+10mg+12,5mg 100tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - valsartaan+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 320mg+10mg+25mg 30tk; 320mg+10mg+25mg 14tk; 320mg+10mg+25mg 90tk; 320mg+10mg+25mg 98tk; 320mg+10mg+25mg 100tk; 320mg+10mg+25mg 56tk; 320mg+10mg+25mg 280tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - valsartaan+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 160mg+10mg+25mg 280tk; 160mg+10mg+25mg 98tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - valsartaan+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 160mg+5mg+25mg 280tk; 160mg+5mg+25mg 14tk; 160mg+5mg+25mg 60tk; 160mg+5mg+25mg 100tk; 160mg+5mg+25mg 28tk; 160mg+5mg+25mg 98tk; 160mg+5mg+25mg 90tk; 160mg+5mg+25mg 30tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - palonosetroon - süstelahus - 50mcg 1ml 5ml 1tk; 50mcg 1ml 5ml 5tk; 50mcg 1ml 5ml 2tk; 50mcg 1ml 5ml 3tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - valsartaan+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 160mg+5mg+12,5mg 100tk; 160mg+5mg+12,5mg 14tk; 160mg+5mg+12,5mg 28tk; 160mg+5mg+12,5mg 56tk; 160mg+5mg+12,5mg 60tk

Eesti - eesti - Ravimiamet

colep laupheim gmbh & co. kg - kamper+metüülsalitsülaat+levomentool - salv - 90mg+3,3mg+13,5mg 1g 30g 1tk

Eesti - eesti - Ravimiamet

grindeks as - bensüülnikotinaat+nonivamiid+kamper+tärpentiniõli+dimetüülsulfoksiid - salv - 20mg+2mg+30mg+30mg+50mg 1g 50g 1tk; 20mg+2mg+30mg+30mg+50mg 1g 30g 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - atezolüsumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastilised ained - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitteväikerakk-kopsuvähi pärast eelnevat keemiaravi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.